M&A Advisor for Ambulatory Surgical Center Owners: 2026 Sell-Side Guide

By Christoph Totter, CT Acquisitions Managing Partner. Last reviewed: July 2026.

Selecting an M&A advisor for an ambulatory surgical center (ASC) is a different exercise than selecting one for a physician practice, a hospital carve-out, or a diagnostics platform. ASC transactions live at the intersection of physician syndication mechanics, hospital joint-venture structures, CMS reimbursement policy, state Certificate of Need (CON) statutes, and the anti-kickback safe harbor for surgeon investment under 42 CFR 1001.952(r). The buyer universe for a well-run multi-specialty ASC in 2026 is narrow, sophisticated, and led by four consolidators: United Surgical Partners International (USPI), a Tenet Healthcare subsidiary, Surgery Partners (NASDAQ: SGRY), SCA Health, part of Optum inside UnitedHealth Group, and AmSurg. This guide sets out how the sell-side process runs for an ASC, what moves the multiple, the boutique M&A advisors that specialize in the vertical, and where CT Acquisitions fits for lower-middle-market owners.

Executive summary

ASC transactions cluster around four national platforms (USPI, Surgery Partners, SCA Health, AmSurg) and a growing tail of PE-backed specialty roll-ups per Becker’s ASC Review deal tracking. Reported enterprise-value-to-EBITDA multiples for controlled or majority ASC interests would range from the high-single digits for single-specialty, single-site centers to the mid-teens for multi-specialty platforms with strong out-of-network mix and hospital JV optionality, per the annual VMG Health ASC Valuation Multiples Survey .

• ASC transactions cluster around four national platforms (USPI, Surgery Partners, SCA Health, AmSurg) and a growing tail of PE-backed specialty roll-ups per Becker’s ASC Review deal tracking.
• Reported enterprise-value-to-EBITDA multiples for controlled or majority ASC interests would range from the high-single digits for single-specialty, single-site centers to the mid-teens for multi-specialty platforms with strong out-of-network mix and hospital JV optionality, per the annual VMG Health ASC Valuation Multiples Survey.
• Surgery Partners’ publicly disclosed pipeline in its SEC 10-K filings shows continued center-level acquisitions at aggregate multiples materially above single-site private benchmarks.
• Tenet Healthcare’s 10-K disclosures report USPI as the platform driving segment growth, with a stated strategy of adding centers annually.
• State CON laws, tracked by the National Conference of State Legislatures, remain a binary variable: a CON-protected ASC in a restrictive state would command a scarcity premium that a Texas or California ASC would not.
• Physician syndication (typically 30 to 49 percent physician ownership) is required for anti-kickback safe harbor per HHS OIG guidance, and syndication depth is a top-five value driver.
• The CMS ASC Payment System and its rate relationship to the Hospital Outpatient Prospective Payment System (HOPD) is the single biggest reimbursement variable, revisited annually via the ASC/HOPD final rule.

Key findings

Ambulatory surgery is one of the highest-conviction PE consolidation theses in healthcare, evidenced by Tenet’s continued platform investment in USPI as reported in its annual 10-K . Bain Capital’s take-private of Surgery Partners was announced in 2025, per the Surgery Partners investor relations page , signaling continued strategic appetite for the platform. ASC valuation is driven by specialty mix, out-of-network exposure, payor concentration, physician syndication, and hospital JV status, per.

1. Ambulatory surgery is one of the highest-conviction PE consolidation theses in healthcare, evidenced by Tenet’s continued platform investment in USPI as reported in its annual 10-K.
2. Bain Capital’s take-private of Surgery Partners was announced in 2025, per the Surgery Partners investor relations page, signaling continued strategic appetite for the platform.
3. ASC valuation is driven by specialty mix, out-of-network exposure, payor concentration, physician syndication, and hospital JV status, per VMG Health.
4. Multi-specialty centers with orthopedic, spine, or cardiovascular case mix would trade meaningfully above single-specialty GI or ophthalmology centers, per HealthCare Appraisers published benchmarks.
5. Certificate of Need is a structural moat in roughly 30 states and the District of Columbia per NCSL, and CON status can add multiple turns of EBITDA.
6. The anti-kickback safe harbor at 42 CFR 1001.952(r) governs how surgeon investors can hold equity, and any transaction structure must preserve it.
7. Anesthesia arrangements, historically structured as “Company Model” entities, drew OIG advisory opinion scrutiny and must be diligenced pre-sale.
8. Bain & Company’s Global Healthcare Private Equity Report continues to name ambulatory surgery as a top-three provider subsector for buyout capital.
9. The VMG Health ASC Valuation Multiples Survey is the authoritative published multiples dataset and should be cited in every ASC valuation opinion.
10. Lower-middle-market ASCs ($1M to $10M EBITDA) would clear at a discount to platform benchmarks, which is where a specialist LMM advisor materially changes outcomes.

What M&A multiples do ambulatory surgical centers command by size band in 2026?

Ambulatory surgical center M&A multiples in 2026 would cluster in three bands defined by EBITDA scale, specialty mix, and platform readiness. The table below reflects published guidance from VMG Health , HealthCare Appraisers , and disclosed public-buyer aggregates from Surgery Partners 10-K filings . All ranges are conditional and vertical-specific. Band EBITDA range Typical center profile Reported EV/EBITDA range Single-site, single-specialty $500K to $2M GI or ophthalmology solo center, in-network.

Ambulatory surgical center M&A multiples in 2026 would cluster in three bands defined by EBITDA scale, specialty mix, and platform readiness. The table below reflects published guidance from VMG Health, HealthCare Appraisers, and disclosed public-buyer aggregates from Surgery Partners 10-K filings. All ranges are conditional and vertical-specific.

Band	EBITDA range	Typical center profile	Reported EV/EBITDA range
Single-site, single-specialty	$500K to $2M	GI or ophthalmology solo center, in-network dominant, minimal syndication depth	5.0x to 7.5x per VMG Health
Single-site, multi-specialty	$2M to $5M	Ortho, pain, ENT, GI mixed; broad payor mix; deep syndication	7.5x to 10.0x per HealthCare Appraisers
Multi-site or hospital JV platform	$5M to $15M+	Two or more centers, hospital JV in place or optional, ortho or spine mix, CON protection possible	10.0x to 14.0x+ per Surgery Partners disclosed acquisitions

Ranges above blend controlled and majority interests. Minority physician syndication buy-ins and hospital JV recapitalizations transact at different reference points and would be a category error to combine with control-transaction ranges. Every actual outcome would depend on payor mix, out-of-network exposure, case volume trend, and post-close physician retention agreements.

What moves the ambulatory surgical center multiple

Ten factors determine where an ambulatory surgical center transaction would land inside the ranges above. Ranking is drawn from VMG Health commentary, HealthCare Appraisers ASC benchmarks, and observed acquirer diligence patterns.

Ten factors determine where an ambulatory surgical center transaction would land inside the ranges above. Ranking is drawn from VMG Health commentary, HealthCare Appraisers ASC benchmarks, and observed acquirer diligence patterns.

1. Specialty mix

Orthopedic, spine, and cardiovascular case mix commands the highest multiples. Total joint arthroplasty migrated to ASC settings after CMS removed total knee arthroplasty from the inpatient-only list, as documented in the CMS ASC final rule history. GI and ophthalmology centers, while operationally clean, would command lower multiples due to commoditization and payor pressure.

2. Payor mix and out-of-network exposure

Centers with heavy out-of-network (OON) reimbursement historically posted higher EBITDA but face regulatory risk. The No Surprises Act constrained balance billing in OON scenarios beginning January 2022, compressing certain OON margins. Buyers would apply a haircut to OON-dependent EBITDA in any 2026 diligence.

3. Physician syndication depth

Deep, active physician-investor syndication (typically 30 to 49 percent physician ownership) is required for the anti-kickback safe harbor at 42 CFR 1001.952(r). Centers with concentrated ownership in one or two surgeons face key-person risk and would price lower.

4. Certificate of Need status

A CON in a restrictive state such as North Carolina or Georgia is a structural moat. NCSL catalogues state CON laws, which vary from prohibition of new ASCs to open licensure. A CON-protected ASC would command a scarcity premium.

5. Hospital JV status

A tri-party joint venture with a hospital system, a national platform, and physician investors is the strategic gold standard. Platforms including USPI and SCA Health are structured around this model per Tenet Healthcare and UnitedHealth Group disclosures.

6. Case volume trend

Trailing 24-month case volume growth, decomposed by specialty and surgeon, is diligenced at a granularity below EBITDA. A flat or declining trend on a headline-growing revenue line signals rate rather than volume growth and would compress the multiple.

7. Surgeon retention risk

Buyers underwrite post-close surgeon retention. Rollover equity, non-competes where enforceable, and multi-year professional services agreements are underwritten line by line. Surgeon age concentration and near-term retirements are the largest quiet risks.

8. Anesthesia arrangement structure

Legacy “Company Model” anesthesia arrangements faced OIG scrutiny, including Advisory Opinion 12-06. Buyers would require legal opinions on any anesthesia joint-venture structure and may restructure pre-close.

9. Real estate ownership

ASC real estate is often owned by the physician investors through a separate LLC. Sale-leaseback structuring, lease term, and rent reasonableness (fair market value opinion) all bear on the transaction. Buyers frequently prefer to acquire the operating business and leave real estate with the surgeons under a triple-net lease.

10. Anti-kickback and Stark compliance

Prior compliance audits, whistleblower history, and any open HHS OIG exposure move the multiple in one direction only. A clean compliance file is table stakes.

Who are the active buyers of ambulatory surgical centers in 2026?

The active-buyer universe for ambulatory surgical centers in 2026 is concentrated among four platforms plus a tail of specialty roll-ups. Each is described neutrally below with a citation link. Any owner running a sell-side process would expect all four platforms to be invited into the first-round dataroom.

The active-buyer universe for ambulatory surgical centers in 2026 is concentrated among four platforms plus a tail of specialty roll-ups. Each is described neutrally below with a citation link. Any owner running a sell-side process would expect all four platforms to be invited into the first-round dataroom.

United Surgical Partners International (USPI)

USPI, a subsidiary of Tenet Healthcare (NYSE: THC) is the largest ASC operator in the United States by center count. Tenet’s 10-K filings report continued USPI center additions annually, with a preference for tri-party JV structures with hospital partners.

Surgery Partners (NASDAQ: SGRY)

Surgery Partners is a publicly traded ASC and short-stay surgical hospital operator. Its 10-K disclosures describe an active center-level acquisition program, and Bain Capital’s announced take-private in 2025 (per Surgery Partners investor relations) reinforces the platform thesis.

SCA Health (part of Optum, UnitedHealth Group)

SCA Health, part of Optum within UnitedHealth Group (NYSE: UNH), operates a large ambulatory surgery portfolio and pursues both single-center acquisitions and multi-site platform deals. SCA competes directly with USPI and Surgery Partners on the largest opportunities.

AmSurg

AmSurg, part of the Envision Healthcare family, historically focused on GI and ophthalmology and remains active in single-specialty consolidation.

Regent Surgical Health

Regent Surgical Health is a specialty ASC development and management company that partners with hospitals and physicians on greenfield and acquisition-based JVs.

Specialty PE roll-ups

Beyond the four national platforms, private equity has funded specialty-focused ASC platforms in ophthalmology, GI, orthopedics, and dermatology. PitchBook and Becker’s ASC Review track these platforms; naming a specific ophthalmology or GI platform in this guide would risk misattribution as sponsor ownership rotates, so owners should confirm current ownership at diligence via PitchBook or SEC filings.

Which boutique M&A advisors specialize in ambulatory surgical centers?

Three boutique advisory firms would be expected to appear in any ASC owner’s advisor shortlist based on published thought leadership, transaction announcements, and public benchmarking work. Each is described neutrally below.

Three boutique advisory firms would be expected to appear in any ASC owner’s advisor shortlist based on published thought leadership, transaction announcements, and public benchmarking work. Each is described neutrally below.

VMG Health

VMG Health is a healthcare-focused valuation, transaction advisory, and strategy firm that publishes the annual ASC Valuation Multiples Survey, the most-cited public benchmark for the vertical. VMG’s ASC practice covers fair market value opinions, sell-side and buy-side transaction advisory, and JV structuring.

Provident Healthcare Partners

Provident Healthcare Partners is a middle-market investment banking boutique focused on healthcare services, with an active ambulatory surgery practice and published sector research including ASC-specific commentary.

HealthCare Appraisers

HealthCare Appraisers publishes ASC benchmark data and performs fair market value opinions used in physician syndication buy-ins, hospital JV formations, and safe-harbor documentation. Its ASC benchmark surveys are widely referenced.

CT Acquisitions positioning

CT Acquisitions is another lower-middle-market option specializing in $1M to $50M EBITDA sell-side and buy-side mandates. For ASC owners at the lower end of the size spectrum (single-site, sub-$5M EBITDA) who want an owner-aligned fee structure and a run process that invites all four national platforms and the relevant specialty PE roll-ups, CT is a fair alternative to the specialists above. The named specialist firms (VMG Health, Provident, HealthCare Appraisers) hold decades of vertical-specific research and are the incumbents. CT positions on LMM ASC deals where a full national-platform auction plus rigorous physician-syndication documentation is warranted and where owner alignment on fees matters. See M&A advisor fees in 2026 and how M&A advisors compare to business brokers for the fee framework.

How the sell-side process works for an ambulatory surgical center

The sell-side process for an ASC runs on a 6 to 9 month timeline for a well-prepared center. Timing lengthens where physician syndication documentation, CON diligence, or hospital JV consent is complex. The month-by-month cadence below is typical of a full-process auction and mirrors CT’s investment banking process for selling a company .

The sell-side process for an ASC runs on a 6 to 9 month timeline for a well-prepared center. Timing lengthens where physician syndication documentation, CON diligence, or hospital JV consent is complex. The month-by-month cadence below is typical of a full-process auction and mirrors CT’s investment banking process for selling a company.

Month 1: preparation

Engage the advisor. Assemble the transaction documentation set: audited financials, case volume by specialty and surgeon, payor mix, syndication cap table, CON documentation if applicable, compliance file, real estate lease. Commission a sell-side quality of earnings report to underwrite EBITDA adjustments.

Month 2: marketing materials and buyer list

Prepare the confidential information memorandum (CIM) and teaser. Build the buyer list. For an ASC this would include the four national platforms, three to six relevant specialty PE roll-ups, and one or two regional hospital systems where a JV would be strategically compelling.

Month 3: first-round outreach

Distribute the teaser under NDA. Deliver CIMs to interested buyers. Set an indication-of-interest (IOI) deadline. First-round outreach typically produces 8 to 15 IOIs on a well-run ASC process.

Month 4: management meetings

Host management meetings with 4 to 6 shortlisted buyers. Grant limited data-room access. Negotiate second-round bid parameters.

Month 5: letter of intent

Receive second-round bids and negotiate an exclusive letter of intent. LOI negotiation for an ASC includes structure (equity purchase versus JV recapitalization), rollover equity for surgeon-owners, working capital peg, and physician-retention terms.

Months 6 to 7: confirmatory diligence

Buyer conducts confirmatory financial, legal, regulatory, and clinical diligence. Anti-kickback and Stark compliance review is central. Anesthesia arrangements are scrutinized. Real estate lease is redlined.

Month 8: definitive documentation

Negotiate the purchase agreement, JV operating agreement (if applicable), employment and non-compete agreements, and any real estate documents.

Month 9: closing

Regulatory filings including HSR if applicable, change-of-ownership (CHOW) filings with Medicare, state licensure transfer, and closing. See CT’s due diligence checklist for sellers for the diligence workstream in detail.

What regulatory and structural mechanics affect ambulatory surgical center M&A in 2026?

ASC transactions in 2026 must navigate five specific regulatory and structural mechanics. None is optional and each shapes deal structure.

ASC transactions in 2026 must navigate five specific regulatory and structural mechanics. None is optional and each shapes deal structure.

Anti-kickback safe harbor for surgeon investment

The safe harbor at 42 CFR 1001.952(r) requires that physician investors use the ASC for one-third of their outpatient surgical procedures, that returns be proportional to capital investment, and that investment terms not be conditioned on referrals. Any post-close syndication structure must preserve compliance.

Certificate of Need

NCSL catalogues state CON laws. Roughly 30 states plus DC maintain some form of CON regime, though scope varies. A CON-protected ASC in North Carolina, Georgia, or South Carolina would command a scarcity premium. States with no CON, including Texas and California, would price closer to open-market benchmarks.

CMS ASC-PPS payment

The CMS ASC Payment System updates annually via the ASC/HOPD final rule. Site-neutral payment discussion, HOPD/ASC parity legislation, and inpatient-only list migration each affect near-term revenue trajectory.

No Surprises Act and out-of-network compression

The No Surprises Act constrained OON balance billing beginning January 2022. Buyers apply structural haircuts to OON-dependent EBITDA and would model in-network conversion scenarios.

Anesthesia and ancillary joint ventures

OIG has issued guidance on ASC-anesthesia arrangements including Advisory Opinion 12-06. Legacy structures may be restructured pre-close. Ancillary businesses (imaging, pathology, pharmacy) require separate compliance review.

How to choose an M&A advisor for an ambulatory surgical center

A defensible advisor selection process for an ASC owner would cover the following ten points. Any advisor unwilling to answer these in writing is not the right advisor. Vertical experience. Number of closed ASC transactions in the last 36 months, by specialty mix. Ask for representative transaction announcements or references. Buyer relationships. Named contacts at USPI, Surgery Partners, SCA Health, AmSurg, and Regent, plus the relevant specialty PE platforms. Physician.

A defensible advisor selection process for an ASC owner would cover the following ten points. Any advisor unwilling to answer these in writing is not the right advisor.

1. Vertical experience. Number of closed ASC transactions in the last 36 months, by specialty mix. Ask for representative transaction announcements or references.
2. Buyer relationships. Named contacts at USPI, Surgery Partners, SCA Health, AmSurg, and Regent, plus the relevant specialty PE platforms.
3. Physician syndication documentation. Familiarity with cap-table cleanup, fair market value opinions, and safe-harbor compliance under 42 CFR 1001.952(r).
4. Hospital JV experience. Whether the advisor has structured tri-party JVs with a hospital system, a national platform, and physician investors.
5. CON and licensure navigation. Track record on CON diligence, state licensure transfer, and Medicare CHOW.
6. Quality of earnings support. Coordination with a healthcare-experienced QoE provider on syndication distributions, related-party payments, and anesthesia arrangements.
7. Fee structure and owner alignment. Retainer, success fee, and any tail-period obligations. See M&A advisor fee structure and the M&A advisor retainer guide.
8. Confidentiality management. How the advisor manages the confidentiality of a process where surgeon investors, hospital partners, and payors could learn of the sale.
9. Post-close employment negotiation. Experience negotiating multi-year professional services agreements, non-competes where enforceable, and rollover equity for surgeon-owners.
10. References from prior ASC clients. Two or three references from prior closed ASC sales, with permission to contact directly.

What EBITDA multiples apply by deal size in 2026?

EBITDA multiples for lower middle market businesses vary by size, buyer type, and vertical. The table below shows typical bands for privately-held sellers in 2026 based on GF Data and Axial 2025 benchmarks.

EBITDA size band	Typical multiple	Dominant buyer type
$500K to $1M	3.0x to 4.5x	Individual buyers, ETA, small local PE
$1M to $3M	4.0x to 6.0x	Search funds, small PE, family offices
$3M to $10M	5.5x to 8.0x	Lower middle market PE, strategic tuck-ins
$10M to $25M	7.0x to 10.5x	Middle market PE platforms, strategic acquirers

Frequently asked questions

What multiple does an ambulatory surgical center sell for in 2026?

A single-site, single-specialty ASC would clear at 5.0x to 7.5x EBITDA per VMG Health. Single-site multi-specialty centers would clear at 7.5x to 10.0x. Multi-site or hospital-JV platforms with orthopedic or spine mix have transacted at 10.0x to 14.0x or above based on Surgery Partners disclosed aggregate multiples. Actual outcomes depend on specialty mix, CON status, and payor mix.

Who are the biggest buyers of ambulatory surgical centers?

The four largest active acquirers in 2026 are USPI (Tenet Healthcare), Surgery Partners (NASDAQ: SGRY), SCA Health (Optum), and AmSurg. Beyond the national platforms, specialty PE roll-ups compete for single-specialty centers, and regional hospital systems consider tri-party JVs with national platforms.

Do I need physician syndication to sell my ASC?

Buyers strongly prefer deep, active physician syndication (typically 30 to 49 percent physician ownership) because it preserves the anti-kickback safe harbor at 42 CFR 1001.952(r) and secures post-close case volume. Centers with concentrated single-surgeon ownership face key-person haircuts.

How does Certificate of Need affect my ASC valuation?

A CON in a restrictive state is a structural moat that constrains new entrants. NCSL catalogues state CON laws. CON-protected centers would command scarcity premiums that open-licensure states such as Texas and California would not offer.

How long does an ASC sale take?

Six to nine months from advisor engagement to closing for a well-prepared center. Complex physician syndication cap tables, hospital JV consents, and CON diligence can extend timelines. See CT’s investment banking process for selling a company.

What is a hospital JV and why does it raise the multiple?

A tri-party joint venture combines a hospital system, a national ASC platform, and physician investors. Platforms including USPI (per Tenet Healthcare) and SCA Health (per UnitedHealth Group) are structured around this model. Hospital JVs secure payor contracting leverage, referral flow, and strategic optionality that raise the multiple.

Should I sell to a strategic or a PE-backed platform?

Both are viable. Strategics (USPI, SCA Health, AmSurg) offer integrated hospital-system relationships and long-hold capital. PE-backed platforms including Surgery Partners under Bain (per Surgery Partners investor relations) offer speed and rollover equity optionality. See strategic buyer versus financial buyer for the tradeoff framework.

What advisor fees should I expect?

Middle-market M&A advisor fees typically combine a modest retainer and a success fee scaled to transaction value. See M&A advisor fees in 2026, M&A advisor cost, and M&A advisor fee structure for detailed benchmarking.

Methodology and data sources

This guide relies on the following primary and secondary sources: the annual VMG Health ASC Valuation Multiples Survey ; published ASC benchmarks from HealthCare Appraisers ; SEC filings from Tenet Healthcare (NYSE: THC) and Surgery Partners (NASDAQ: SGRY) ; disclosures from UnitedHealth Group ; industry commentary from Becker’s ASC Review ; deal t…

This guide relies on the following primary and secondary sources: the annual VMG Health ASC Valuation Multiples Survey; published ASC benchmarks from HealthCare Appraisers; SEC filings from Tenet Healthcare (NYSE: THC) and Surgery Partners (NASDAQ: SGRY); disclosures from UnitedHealth Group; industry commentary from Becker’s ASC Review; deal tracking from PitchBook; the CMS ASC Payment System; the safe-harbor regulation at 42 CFR 1001.952(r); HHS OIG guidance and advisory opinions; the NCSL Certificate of Need database; the No Surprises Act CMS resources; and Bain & Company’s Global Healthcare Private Equity Report. All multiples ranges are reported as ranges rather than points, use conditional tense, and are not appraisals.

This report is not an appraisal, not investment advice, not legal advice, not tax advice, not financial advice, and not a prediction. It is educational content prepared by Christoph Totter, Managing Partner of CT Acquisitions, for the benefit of ambulatory surgical center owners considering exit or capital-partner alternatives. Owners considering a transaction should retain licensed counsel, a fair market value provider, and a healthcare-experienced M&A advisor. See CT’s M&A advisory practice and sister vertical guides including M&A advisor for dental practice and M&A advisor for veterinary practice.